Summary
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
History
In 2015, Intrexon purchased Oxitec, a maker of genetically sterile insects, for $160 million. In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy to treat acute myeloid leukemia. In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing. With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.
Mission
Our mission is to discover and develop novel biotherapeutics to improve the lives of patients and accelerate the delivery of significant medical advancements.
Vision
Our vision is to be a leader in the world of biologics, driving innovation and enabling accelerated delivery of groundbreaking therapies that address life-threatening medical conditions.
Key Team
Mr. Donald P. Lehr (Chief Legal Officer & Corp. Sec.)
Mr. Jeffrey Thomas Perez (Sr. VP of Intellectual Property Affairs)
Dr. Thomas D. Reed (Founder & Chief Science Officer)
Mr. Rutul R. Shah (Chief Operating Officer)
Mr. Steven Harasym (VP & Head of Investor Relations)
Marie Rossi (VP of Communications)
Mr. Rob Russell (VP & Head of HR)
Recognition and Awards
Precigen has been recognized by leading industry awards, such as the Institute of Genetics Award for Excellence in Gene Therapy, the BioGenerator Award for Emerging Companies and the Wall Street Journal’s World-Wide Innovator Award.
References
United States 